Correlation Between Gilead Sciences and Telomir Pharmaceuticals,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Gilead Sciences and Telomir Pharmaceuticals, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Gilead Sciences and Telomir Pharmaceuticals, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Gilead Sciences and Telomir Pharmaceuticals, Common, you can compare the effects of market volatilities on Gilead Sciences and Telomir Pharmaceuticals, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Gilead Sciences with a short position of Telomir Pharmaceuticals,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Gilead Sciences and Telomir Pharmaceuticals,.

Diversification Opportunities for Gilead Sciences and Telomir Pharmaceuticals,

-0.6
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Gilead and Telomir is -0.6. Overlapping area represents the amount of risk that can be diversified away by holding Gilead Sciences and Telomir Pharmaceuticals, Commo in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Telomir Pharmaceuticals, and Gilead Sciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Gilead Sciences are associated (or correlated) with Telomir Pharmaceuticals,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Telomir Pharmaceuticals, has no effect on the direction of Gilead Sciences i.e., Gilead Sciences and Telomir Pharmaceuticals, go up and down completely randomly.

Pair Corralation between Gilead Sciences and Telomir Pharmaceuticals,

Given the investment horizon of 90 days Gilead Sciences is expected to generate 0.18 times more return on investment than Telomir Pharmaceuticals,. However, Gilead Sciences is 5.65 times less risky than Telomir Pharmaceuticals,. It trades about 0.13 of its potential returns per unit of risk. Telomir Pharmaceuticals, Common is currently generating about 0.0 per unit of risk. If you would invest  8,281  in Gilead Sciences on September 13, 2024 and sell it today you would earn a total of  957.00  from holding Gilead Sciences or generate 11.56% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Gilead Sciences  vs.  Telomir Pharmaceuticals, Commo

 Performance 
       Timeline  
Gilead Sciences 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Gilead Sciences are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of rather inconsistent essential indicators, Gilead Sciences may actually be approaching a critical reversion point that can send shares even higher in January 2025.
Telomir Pharmaceuticals, 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Telomir Pharmaceuticals, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy essential indicators, Telomir Pharmaceuticals, is not utilizing all of its potentials. The newest stock price disarray, may contribute to short-term losses for the investors.

Gilead Sciences and Telomir Pharmaceuticals, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Gilead Sciences and Telomir Pharmaceuticals,

The main advantage of trading using opposite Gilead Sciences and Telomir Pharmaceuticals, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Gilead Sciences position performs unexpectedly, Telomir Pharmaceuticals, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telomir Pharmaceuticals, will offset losses from the drop in Telomir Pharmaceuticals,'s long position.
The idea behind Gilead Sciences and Telomir Pharmaceuticals, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Other Complementary Tools

Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data